MEI Pharma, Inc. 是一家从事药品化合物开发的制药公司。公司总部位于美国加利福尼亚州圣地亚哥,目前拥有28名全职员工。该公司于2003年12月18日上市。该公司的资金管理计划以莱特币为依托。公司已终止Voruciclib的临床开发,但与候选药物资产相关的某些非临床活动仍在继续进行。在评估战略选择的过程中,公司可能会考虑现有项目的对外许可机会以及并购机会。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for LITS. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: LITS is a Sell candidate.
LITS stock price ended at $0.97 on 星期三, after rising 5.43%
On the latest trading day Jul 01, 2026, the stock price of LITS rose by 5.43%, climbing from $0.94 to $0.97. Throughout the session, the stock experienced a volatility of 8.99%, with prices fluctuating between a daily low of $0.89 and a high of $0.97. Alongside this price increase, trading volume also rose by 306.8K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 95.0K shares were traded, amounting to a market value of approximately $33.0M.